A Safe, Orally Administered Agent for Dengue [ 2017 - 2019 ]

Research Grant

Researchers: Prof David Jans (Principal investigator) ,  Dr Kylie Wagstaff ,  Prof Christopher Porter ,  Prof Subhash Vasudevan ,  Prof Susan Charman

Brief description Dengue virus is the most important mosquito-borne viral disease, with 2/3 of the world's population at risk. There is currently no treatment available for dengue. Our proposal aims to progress a safe and effective new treatment (4-HPR) against Dengue towards the clinic, generating all the required pharmacokinetic and pre-clinical animal data necessary to progress to a future clinical trial in humans. We will also investigate the use of 4-HPR as a dengue preventative.

Funding Amount $AUD 877,454.12

Funding Scheme Development Grants

Notes Development Grant